Skip to content
Review Open access

Inclisiran: A Novel Agent in the Management of Hypercholesterolemia

Dec 2026 · International Journal of Cardiology Research & Reviews · 0 citations

Abstract

PCSK9 is a serine protease that binds to the LDL receptors and targets the receptors for lysosomal degradation, thus reducing their recycling and decreasing the removal rate of circulating LDL-C. Monoclonal antibodies directed against PCSK9, such alirocumab and evolocumab, have been shown to cause a significant reduction in LDL-C levels and improve cardiovascular outcomes. On the other hand, inclisiran is a chemically synthesized siRNA molecule, which lowers LDL-C levels by targeting the hepatic production of PCSK9, as it prevents its translation via degradation of PCSK9 mRNA post-transcription. This review aims to discuss the current evidence regarding the role of inclisiran in the management of hypercholesterolemia.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.